- Oops!Something went wrong.Please try again later.
- Oops!Something went wrong.Please try again later.
HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of this bearish move was mostly centered around fear of the impact the U.S. China trade war would have on global trade. Since Trump began reporting positive news on talks with President Xi, the market has started to rally. One sector that this has helped is biotech. Today, we are exploring opportunities in the market with upside potential in this recovery.
One possible example of an oversold biotech with upside potential is Delcath Systems, Inc. (DCTH). Last September, the stock reached highs above $8 and is now sitting around support at $0.26. With promising liver cancer treatments in development (multiple Phase 3 clinical trials) and a new licensing deal with a projected value of up to $45 million, there is a lot to intrigue potential investors. With not much awareness among investors yet we think it would be prudent to research DCTH now.
Today we are highlighting: Delcath Systems, Inc. (DCTH), Celldex Therapeutics, Inc. (CLDX), Geron Corporation (GERN), Aevi Genomic Medicine, Inc. (GNMX), and Histogenix Corporation (NASDAQ: HSGX).
An interventional oncology company focused on treating liver cancers with major upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $2.953M, Share Price: $0.2646), is an interventional oncology company focused on treating liver cancers. Last year they announced an amendment to their Phase 3 ocular melanoma clinical trial, raised $7 million via a right offering, increased revenue 20% Y/Y, and had data published in European Radiology among several other milestones.
DCTH made big news recently entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.
If the Company is able to complete enrollment in its Phase 3 ocular melanoma trial this year, there is potential for significant upside. Research DCTH now.
Celldex Therapeutics, Inc. (CLDX) (Market Cap: $56.086M, Share Price: $0.3252) presented data from the Company's MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rdAnnual Meeting. MerTK is emerging as a promising target for cancer immunotherapy.
Geron Corporation (GERN) (Market Cap: $190.075M, Share Price: $1.02) announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019.
Aevi Genomic Medicine, Inc. (GNMX) (Market Cap: $13.277M, Share Price: $0.2050) announced that the ASCEND trial, a genomically-guided Phase 2 double-blind, placebo-controlled clinical trial of orally-administered AEVI-001 (100 - 400 mg BID) in children aged 6 - 17 with Attention Deficit Hyperactivity Disorder (ADHD) with an mGluR copy number variant (Part A) or without an mGluR copy number variant (Part B), did not achieve statistical significance on the primary endpoint of reduction of ADHD-RS in either Part A or Part B after 6 weeks of treatment with AEVI-001. AEVI-001 was safe and well tolerated. Reported adverse events were minimal and similar across both Part A and Part B treatment groups.
Histogenix Corporation (HSGX) (Market Cap: $9.105M, Share Price: $0.1468) reported an update on their NeoCart regulatory pathway based on discussions with the FDA indicating that an additional trial would need to be completed before it would accept submission of a Biologics License Application for NeoCart.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Microspeculators.com Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States
SOURCE: Regal Consulting, LLC